These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34310251)

  • 1. Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies.
    Buonomo AR; Viceconte G; Zappulo E; Maraolo AE; Russo CV; Carotenuto A; Moccia M; Gentile I
    Expert Opin Drug Saf; 2021 Oct; 20(10):1237-1246. PubMed ID: 34310251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Zappulo E; Viceconte G; Scotto R; Borgia G; Gentile I
    Expert Opin Drug Saf; 2018 Jul; 17(7):709-717. PubMed ID: 29848085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review.
    Scotto R; Reia A; Buonomo AR; Moccia M; Viceconte G; Pisano E; Zappulo E; Brescia Morra V; Gentile I
    Expert Opin Drug Saf; 2021 Aug; 20(8):925-936. PubMed ID: 33880975
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
    Scappaticcio L; Castellana M; Virili C; Bellastella G; Centanni M; Cannavò S; Campennì A; Ruggeri RM; Giovanella L; Trimboli P
    J Endocrinol Invest; 2020 Feb; 43(2):219-229. PubMed ID: 31452116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
    Wray S; Havrdova E; Snydman DR; Arnold DL; Cohen JA; Coles AJ; Hartung HP; Selmaj KW; Weiner HL; Daizadeh N; Margolin DH; Chirieac MC; Compston DAS
    Mult Scler; 2019 Oct; 25(12):1605-1617. PubMed ID: 30289355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
    Baker D; Giovannoni G; Schmierer K
    Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
    Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
    Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
    Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
    BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
    Herman JA; Khalighinejad F; York K; Radu I; Berrios Morales I; Ionete C; Hemond CC
    Mult Scler Relat Disord; 2021 Jan; 47():102619. PubMed ID: 33189019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
    Massey J; Barnett Y; Curnow J; Sutton I
    Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
    Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
    Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
    Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
    Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.